Regeneron Pharmaceuticals, Inc. REGN

788.04 (7.98) (1.00%) as of 25 Sep
Market cap
$81.3B
P/E
18.8×
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years

Regeneron Pharmaceuticals, Inc. (REGN) EV/Sales

As of 25 September 2026, Regeneron Pharmaceuticals, Inc. (REGN) trades at a EV/Sales of 4.9×. Over the past ten years it has ranged from 3.3× (June 2025) to 17.9× (June 2015); the current reading is higher than 18% of that period. That is below the Biotechnology industry median of 10.7× and above the Healthcare sector median of 3.6×.

EV/Sales, daily

Annual

Period EV/Sales Change
FY2025 5.3× 4.97%
FY2024 5.0× (26.15%)
FY2023 6.8× 13.57%
FY2022 6.0× 50.84%
FY2021 4.0× (35.91%)
FY2020 6.2× 5.41%
FY2019 5.9× (20.91%)
FY2018 7.4× 9.08%
FY2017 6.8× (15.33%)
FY2016 8.0× (40.32%)

Quarterly

Period EV/Sales Change
Jun 2026 3.8× (23.99%)
Mar 2026 5.0× (5.46%)
Dec 2025 5.3× 41.00%
Sep 2025 3.7× 3.86%
42 more quarters

Against its own ten years

Low 3.3× High 17.9×
Ten-year median 6.4×
Current reading's percentile 18

EV/Sales against peers

Company EV/Sales
REGN Regeneron Pharmaceuticals, Inc. 4.9×
ONC BeOne Medicines Ltd. - Sponsored ADR compare 6.0×
ALNY Alnylam Pharmaceuticals, Inc. compare 6.6×
VRTX Vertex Pharmaceuticals Incorporated compare 10.0×
ARGX argenex SE compare 10.5×
RPRX Royalty Pharma PLC compare 13.4×
INSM Insmed, Inc. compare 22.2×
MRNA Moderna, Inc. compare 33.5×
RVMD Revolution Medicines, Inc. compare 1,499×
Biotechnology industry median 10.7×
Healthcare sector median 3.6×
Market median 2.2×

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on REGN